Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma

Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma

Introduction: Treatment with Sunitinib, a potent multitargeted receptor tyrosine kinase inhibitor (TKI) has increased the progression-free survival (PFS) and overall-survival (OS) of patients with metastasized renal cell carcinoma (mRCC). With modest OS improvement and variable response and toxicity...

Full description

Saved in:
Bibliographic Details
Main Authors: Jeannette C. Oosterwijk-Wakka, Liesbeth Houkes, Loes F.M. van der Zanden, Lambertus A.L.M. Kiemeney, Kerstin Junker, Anne Y Warren, Tim Eisen, Ulrich Jaehde, Marius T Radu, Rob Ruijtenbeek, Egbert Oosterwijk
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Renal Cell Carcinoma
TKI
biomarker
kinase activity
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558624001490
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items